Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram

Chi Un Pae, Sheng Min Wang, Soo Jung Lee, Changsu Han, Ashiwn A. Patkar, Prakash S. Masand

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: Evidence increasingly points to the potential development of harmful cardiac side effects concomitant with the use of a number of psychotropic drugs, primarily traditional antipsychotics and tricyclic antidepressants. Areas covered: The US Food and Drug Administration announced safety warnings associated with the use of citalopram with QT interval prolongation in 2011 and 2012. This paper explores the clinical background of QT interval prolongation, clinical data related to antidepressants and QT interval prolongation, the clinical implications of safety issues associated with the use of antidepressants and future research directions. Expert opinion: Currently available evidence proposes that citalopram may not be definitely associated with the increase of cardiac mortality, although it should be related with increase of QT prolongation. A firm consensus regarding the cardiac safety issues associated with antidepressants has to be established in near future. Hence, the choice of an individual antidepressant regarding cardiac safety issues should be based on multiple factors; clinicians may need to select the best available antidepressant for each individual based on that patient's vulnerability, the proven efficacy and safety of each agent and a reasonable benefit:risk ratio, based on currently available findings.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalExpert Opinion on Drug Safety
Volume13
Issue number2
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Citalopram
Antidepressive Agents
Safety
Tricyclic Antidepressive Agents
Psychotropic Drugs
Expert Testimony
United States Food and Drug Administration
Antipsychotic Agents
Odds Ratio
Mortality

Keywords

  • Antidepressant
  • Benefit
  • Citalopram
  • Depression
  • QT interval prolongation
  • Risk

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. / Pae, Chi Un; Wang, Sheng Min; Lee, Soo Jung; Han, Changsu; Patkar, Ashiwn A.; Masand, Prakash S.

In: Expert Opinion on Drug Safety, Vol. 13, No. 2, 01.02.2014, p. 197-205.

Research output: Contribution to journalReview article

Pae, Chi Un ; Wang, Sheng Min ; Lee, Soo Jung ; Han, Changsu ; Patkar, Ashiwn A. ; Masand, Prakash S. / Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. 2. pp. 197-205.
@article{378d89bbb40049a5aa414469d4e4b98f,
title = "Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram",
abstract = "Introduction: Evidence increasingly points to the potential development of harmful cardiac side effects concomitant with the use of a number of psychotropic drugs, primarily traditional antipsychotics and tricyclic antidepressants. Areas covered: The US Food and Drug Administration announced safety warnings associated with the use of citalopram with QT interval prolongation in 2011 and 2012. This paper explores the clinical background of QT interval prolongation, clinical data related to antidepressants and QT interval prolongation, the clinical implications of safety issues associated with the use of antidepressants and future research directions. Expert opinion: Currently available evidence proposes that citalopram may not be definitely associated with the increase of cardiac mortality, although it should be related with increase of QT prolongation. A firm consensus regarding the cardiac safety issues associated with antidepressants has to be established in near future. Hence, the choice of an individual antidepressant regarding cardiac safety issues should be based on multiple factors; clinicians may need to select the best available antidepressant for each individual based on that patient's vulnerability, the proven efficacy and safety of each agent and a reasonable benefit:risk ratio, based on currently available findings.",
keywords = "Antidepressant, Benefit, Citalopram, Depression, QT interval prolongation, Risk",
author = "Pae, {Chi Un} and Wang, {Sheng Min} and Lee, {Soo Jung} and Changsu Han and Patkar, {Ashiwn A.} and Masand, {Prakash S.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1517/14740338.2013.840583",
language = "English",
volume = "13",
pages = "197--205",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram

AU - Pae, Chi Un

AU - Wang, Sheng Min

AU - Lee, Soo Jung

AU - Han, Changsu

AU - Patkar, Ashiwn A.

AU - Masand, Prakash S.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Introduction: Evidence increasingly points to the potential development of harmful cardiac side effects concomitant with the use of a number of psychotropic drugs, primarily traditional antipsychotics and tricyclic antidepressants. Areas covered: The US Food and Drug Administration announced safety warnings associated with the use of citalopram with QT interval prolongation in 2011 and 2012. This paper explores the clinical background of QT interval prolongation, clinical data related to antidepressants and QT interval prolongation, the clinical implications of safety issues associated with the use of antidepressants and future research directions. Expert opinion: Currently available evidence proposes that citalopram may not be definitely associated with the increase of cardiac mortality, although it should be related with increase of QT prolongation. A firm consensus regarding the cardiac safety issues associated with antidepressants has to be established in near future. Hence, the choice of an individual antidepressant regarding cardiac safety issues should be based on multiple factors; clinicians may need to select the best available antidepressant for each individual based on that patient's vulnerability, the proven efficacy and safety of each agent and a reasonable benefit:risk ratio, based on currently available findings.

AB - Introduction: Evidence increasingly points to the potential development of harmful cardiac side effects concomitant with the use of a number of psychotropic drugs, primarily traditional antipsychotics and tricyclic antidepressants. Areas covered: The US Food and Drug Administration announced safety warnings associated with the use of citalopram with QT interval prolongation in 2011 and 2012. This paper explores the clinical background of QT interval prolongation, clinical data related to antidepressants and QT interval prolongation, the clinical implications of safety issues associated with the use of antidepressants and future research directions. Expert opinion: Currently available evidence proposes that citalopram may not be definitely associated with the increase of cardiac mortality, although it should be related with increase of QT prolongation. A firm consensus regarding the cardiac safety issues associated with antidepressants has to be established in near future. Hence, the choice of an individual antidepressant regarding cardiac safety issues should be based on multiple factors; clinicians may need to select the best available antidepressant for each individual based on that patient's vulnerability, the proven efficacy and safety of each agent and a reasonable benefit:risk ratio, based on currently available findings.

KW - Antidepressant

KW - Benefit

KW - Citalopram

KW - Depression

KW - QT interval prolongation

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=84892747205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892747205&partnerID=8YFLogxK

U2 - 10.1517/14740338.2013.840583

DO - 10.1517/14740338.2013.840583

M3 - Review article

C2 - 24131458

AN - SCOPUS:84892747205

VL - 13

SP - 197

EP - 205

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -